NCT00191230已完成2 期
A Randomized Phase II Trial of Gemcitabine Containing Regimens (Gemcitabine/Carboplatin and Gemcitabine/ Cisplatin)When Used as Preoperative Chemotherapy for Patients With Stage I and II NSCLC
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 70
- 试验地点
- 1
- 主要终点
- Complete pathological response
研究概览
简要总结
To study the efficacy and tolerability of gemcitabine/platinum chemotherapy in non small cell lung cancer
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically of cytologically confirmed non small cell lung cancer
- •No prior chemotherapy or radiation
- •No prior malignancy
排除标准
- •Pregnant or breastfeeding
- •Serious concomitant systemic disorder
结局指标
主要结局
Complete pathological response
次要结局
- Response rate, disease free survival, toxicity including pulmonary toxicity,operative mortality and quality of life.
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Combination of Gemcitabine and Carboplatin in Metastatic or Recurrent Nasopharyngeal CarcinomaNasopharyngeal CarcinomaNCT00697905Ministry of Health, Malaysia18
已完成
2 期
Effects of Carboplatin and Gemcitabine on Stage IIIB Pleural Effusion and Stage IV Lung CancerStage IV Non-small Cell Lung CancerStage IIIB Non-small Cell Lung CancerNCT00247416Susanne Arnold60
终止
1 期
Gemcitabine + Nab-paclitaxel With LDE-225 (Hedgehog Inhibitor) as Neoadjuvant Therapy for Pancreatic AdenocarcinomaPancreatic Ductal AdenocarcinomaNCT01431794Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins23
已完成
2 期
Multicenter Phase 2 Trial Evaluating Cisplatin-Gemcitabine With Concomitant Thoracic Radiotherapy for Treatment of Inoperable Stage III Non Small Cell Lung CancerNon Small Cell Lung CancerNCT00192036Eli Lilly and Company49
进行中（未招募）
1 期
Randomized phase 2 study of gemcitabine/cisplatin with or without SAR240550(BSI-201), a PARP1 inhibitor, in patients with stage IV non-small cell lung canceron-small cell lung cancer stage IV.MedDRA version: 12.1Level: LLTClassification code 10029522Term: Non-small cell lung cancer stage IVEUCTR2009-017270-21-FRsanofi-aventis recherche & développement105